Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Pulmonology
•
Obstructive Lung Disease
•
COPD
Do you check blood eosinophil counts in patients with COPD exacerbations to help guide therapy decisions?
Do findings from the
STARR2
trial influence your approach?
Related Questions
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Will you incorporate ensifentrine in the treatment regimen of patients with COPD on baseline dual or triple inhaler therapy?
Is methacholine challenge on its way out?
Do you use bronchodilator response to distinguish between asthma, COPD, or asthma-COPD overlap?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
Do you routinely consider evaluation for EDAC in patients with asthma or COPD on maximal inhaler therapy who have refractory symptoms?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?